All Wales Medicines Strategy Group

Grŵp Strategaeth Meddyginiaethau Cymru Gyfan

AWMSG ADVICE SUPERSEDED BY
NICE GUIDANCE (TA550)
NICE GUIDANCE ISSUED OCTOBER 2018
(Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

Final Appraisal Recommendation

Advice No: 2514 – September 2014

Vandetanib (Caprelsa®▼)
100 mg and 300 mg film-coated tablets

Submission by Genzyme Therapeutics

Recommendation of AWMSG

Vandetanib (Caprelsa®▼) is not recommended for use within NHS Wales for the treatment of aggressive and symptomatic medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.

The case for cost-effectiveness has not been proven.

Additional notes:

- AWMSG did not consider that vandetanib (Caprelsa®▼) treatment was cost-effective irrespective of whether the medicine was considered under ultra-orphan criteria.
- Patients who are currently being treated with vandetanib (Caprelsa®▼) for the indication stated above should have the option to continue their therapy until they and their clinicians consider it appropriate to stop.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 427), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	AstraZeneca UK Ltd

Date of first issue	September 2014
Last reviewed	December 2017